Optimizing Acute Ischemic Stroke Diagnostics Using Artificial Intelligence
NCT ID: NCT05652933
Last Updated: 2023-10-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2021-12-10
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Improving Stroke Care in North-Norway Through Artificial Intelligence
NCT05903898
Validation of 3D Simulations in Embolic Stroke
NCT05055960
Study on the Performance of a Machine Learning Algorithm Recognizing and Triaging Large Vessel Occlusions Using Non-contrast CT Scans
NCT06216457
Measuring Collaterals With Multi-phase CT Angiography in Patients With Ischemic Stroke
NCT02184936
Trustworthy Artificial Intelligence for Improvement of Stroke Outcomes
NCT06710028
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main objective is to organize and simplify the care pathway to acute stroke imaging powered by cutting edge advances in image processing and artificial intelligence.
The secondary objectives are to assess: 1) the diagnostic accuracy of mCTA in detection of vessel occlusion in ischemic stroke using AI-based analysis tools compared gold standard of MRI, 2) the percentage of eligible patients who receive EVT using AI-based analysis compared to standard care diagnostics 3) time from onset to recanalization, and 4) functional outcome in acute ischemic stroke patients treated with EVT who had their initial radiological diagnosis using AI-based image analysis tools compared to stroke patients diagnosed by standard care.
Hypotheses: Novel AI-based image analysis tools applied to already available standard CT based imaging techniques can a) improve acute stroke diagnostics and b) increase the number of patients treated by EVT.
The main aim of the project is to organise and simplify the care pathway through a pragmatic approach to acute stroke imaging powered by cutting edge advances in image processing and artificial intelligence.
Secondary aims:
1. To assess if the use of AI-based image analysis tools in radiological diagnostics in primary stroke centres can reduce the time from onset to recanalization in acute ischemic stroke patients treated with EVT.
2. To assess the diagnostic accuracy of mCTA in detection of medium and large vessel occlusion ischemic stroke using AI-based analysis tools compared to assessment by the gold standard of MRI (DWI and MR Angiography) assessed by neuroradiologists.
3. To assess the diagnostic accuracy of mCTA in detection of medium and large vessel occlusion ischemic stroke using AI-based analysis tools compared to assessment by standard care.
4. To assess if the use of available AI-based analysis tools applied to mCTA can increase the number of stroke patients eligible for and offered EVT.
5. To compare functional outcome and patient related outcome measures 3 months after EVT in stroke patients who had their initial radiological diagnosis using AI-based image analysis tools to stroke patients diagnosed by standard care.
Endpoints:
Primary Endpoints:
\- Time from the start of CT scan of patients at the local hospital to radiological diagnosis in acute stroke patients with LVO and MeVO in periods with the use of AI software compared to periods with standard care.
Secondary endpoints:
* Time from the start of CT scan of patients at the local hospital to start of thrombectomy in patients identified with LVO and MeVO in periods with the use of AI software compared to periods with standard care.
* Time from symptom onset to start of thrombectomy in patients identified with LVO and MeVO in periods with the use of AI software compared with proportion of patients identified with LVO and MeVO diagnosed by standard care.
* Proportion of patients identified with LVO and MeVO in periods with the use of AI software compared with proportion of patients identified with LVO and MeVO diagnosed by standard care.
* Proportion of patients identified with LVO and MeVO in periods with the use of AI software compared to assessment by neuroradiologists.
* Proportion of patients treated with thrombectomy in MeVO in periods with the use of AI software compared with proportion of patients identified with LVO and MeVO diagnosed by standard care.
* Functional outcome 3 months after EVT in stroke patients who had their initial radiological diagnosis using AI-based image analysis tools compared to stroke patients diagnosed by standard care.
* Patient related outcome measures 3 months after EVT in stroke patients who had their initial radiological diagnosis using AI-based image analysis tools compared to stroke patients diagnosed by standard care.
The present study is part of a prospective observational study of the thrombectomy service with collaboration between stroke units and radiological departments at primary and comprehensive stroke centres - the Oslo Acute Revascularization Stroke Study (OSCAR) (REK 2015/1844, EudraCT number 2018-004691-36). Data has already been collected since January 2017 in patients treated with EVT at Oslo University Hospital and by nearly 1100 patients treated with EVT have been included. The database contains detailed information on logistics, transport, clinical, radiological data, and treatment including rehabilitation from baseline to 3-month follow-up is registered prospectively.
The study will start with a 12-month period with registration before the implementation of the AI software. Data from this period and from the OSCAR study will be compared to the data collected after the implementation of the AI software. We will start the study at Drammen Hospital and will consecutively implement it at the other hospitals in Vestre Viken Hospital Trust and Østfold Hospital Trust. Data will be registered for at least 18 months after the implementation of the AI software. The length of the inclusion phase will be adjusted according to the inclusion rate.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Software for identifying vessel occlusion, infarct volume and penumbra
Assessment of the AI tool software
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All stroke severities and vascular distributions are eligible.
* Informed written consent signed by the patient, verbal consent from the patient as witnessed by a non-participating health care person or consent by the signature of the patient's family must be provided before inclusion. Patients for whom no informed consent can be obtained will not be included in the study but will be treated according to standard guidelines.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vestre Viken Hospital Trust
OTHER
University Hospital of North Norway
OTHER
University of Calgary
OTHER
Oslo University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anne Hege Aamodt
Coordinating Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vestre Viken Hospital Trust
Drammen, , Norway
Oslo University Hospital
Oslo, , Norway
Østfold Hospital Trust
Sarpsborg, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
282961
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.